Abstract: By reviewing the relevant references and reports of the adverse drug reaction cases of Xiyanping in China, and analyzing the post marketing safety studies, the safety and risks in post-marketing period of Xiyanping is reevaluated in this article. The author puts forward risk management measures according to the characteristics of medicine. Suggestions are proposed for a safe and rational use of this medicine.

Key words: Xiyanping injection, safety and risk in post-marketing, risk control, measure